COPD and lung cancer: Epidemiological and biological links;BPCO et cancer bronchique: Liens épidémiologiques et biologiques

Revue des Maladies Respiratoires

Volumn 29, Issue 4, 2012, Pages 545-556

  Prevot, G ^a   Plat, G ^a   Mazieres, J ^a  

^a SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Cancer; COPD; Epidemiology; Genetics; Tobacco

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; EPIGENETICS; HUMAN; LUNG CANCER; LUNG CARCINOMA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84863624256     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.08.009     Document Type: Review

References (77)

1. Fuhrman C, Delmas MC. Epidemiology of chronic obstructive pulmonary disease in France. Rev Mal Respir 2010;27:160-8.
2. Rabe KF, Beghe B, Luppi F, et al. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med 2007;175:1222-32. (Pubitemid 46905748)
3. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503-7. (Pubitemid 16003992)
4. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS One 2009;4: e7380.
5. Wasswa-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005;60:570-5. (Pubitemid 40966211)
6. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007;132:1932-8.
7. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008;178:738-44.
8. Mazieres J, Rouquette I, Brouchet L. Lung cancer in women and pregnancy:towards a hormonal origin? Rev Mal Respir 2007;24:983-97. (Pubitemid 350125331)
9. Prescott E, Bjerg AM, Andersen PK, et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997;10:822-7. (Pubitemid 27180193)
10. Ben-Zaken Cohen S, Pare PD, Man SF, et al. The growing burden of chronic obstructive pulmonary disease and lung cancer in women:examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 2007;176:113-20. (Pubitemid 47057846)
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
12. O'Callaghan DS, O'Donnell D, O'Connell F, et al. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 2010;5:2024-36.
13. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
14. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-9. (Pubitemid 47320803)
15. Barcelo B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4 + CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 2008;31:555-62.
16. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53. (Pubitemid 38787999)
17. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 2002;166:1240-7. (Pubitemid 35222602)
18. Yanai M, Hatazawa J, Ojima F, et al. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998;11:1342-8. (Pubitemid 28298599)
19. Islam SS, Schottenfeld D. Declining FEV1 and chronic productive cough in cigarette smokers:a 25-year prospective study of lung cancer incidence in Tecumseh. Michigan Cancer Epidemiol Biomarkers Prev 1994;3:289-98.
20. Lam S, Shibuya H. Early diagnosis of lung cancer. Clin Chest Med 1999;20:53-61. (Pubitemid 29161851)
21. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35:496-504.
22. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719-26.
23. Zheng W, Blot WJ, Liao ML, et al. Lung cancer and prior tuberculosis infection in Shanghai. Br J Cancer 1987;56:501-4. (Pubitemid 17146360)
24. Liang HY, Li XL, Yu XS, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk:a systematic review. Int J Cancer 2009;125:2936-44.
25. Park SK, Cho LY, Yang JJ, et al. Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study. Lung Cancer 2010;68:20-6.
26. Koshiol J, Rotunno M, Gillison ML, et al. Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst 2011;103:501-7.
27. Qu P, Du H, Wang X, Yan C. Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition. Cancer Res 2009;69:7252-61.
28. Siafakas NM, Antoniou KM, Tzortzaki EG. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007;2:453-62.
29. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer J Mol Med (Berl) 2007;85:1301-7.
30. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284-90. (Pubitemid 43023273)
31. Araya J, Cambier S, Markovics JA, et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest 2007;117:3551-62. (Pubitemid 350097010)
32. Cohen BH, Ball Jr WC, Brashears S, et al. Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol 1977;105:223-32. (Pubitemid 8067888)
33. Bailey-Wilson JE, Amos CI, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004;75:460-74. (Pubitemid 39095821)
34. Joost O, Wilk JB, Cupples LA, et al. Genetic loci influencing lung function:a genome-wide scan in the Framingham Study. Am J Respir Crit Care Med 2002;165:795-9. (Pubitemid 34229649)
35. Yanagitani N, Kohno T, Sunaga N, et al. Localization of a human lung adenocarcinoma susceptibility locus, possibly syntenic to the mouse Pas1 locus, in the vicinity of the D12S1034 locus on chromosome 12p11.2-p12.1. Carcinogenesis 2002;23: 1177-83. (Pubitemid 34814776)
36. de Boer WI, Hau CM, van Schadewijk A, et al. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006;125:184-92. (Pubitemid 43167158)
37. Burgel PR, Nadel JA. Epidermal growth factor receptormediated innate immune responses and their roles in airway diseases. Eur Respir J 2008;32:1068-81.
38. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 2010;17:878-88.
39. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42. (Pubitemid 351483366)
40. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7. (Pubitemid 351483367)
41. Lambrechts D, Buysschaert I, Zanen P, et al. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 2010;181:486-93.
42. Young RP, Hopkins RJ, Hay BA, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008;32:1158-64.
43. Wang J, Spitz MR, Amos CI, et al. Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer 2010;116:3458-62.
44. Yang P, Wentzlaff KA, Katzmann JA, et al. Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:461-5. (Pubitemid 29230552)
45. Taniguchi K, Yang P, Jett J, Bass E, Meyer R, Wang Y, et al. Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clin Cancer Res 2002;8:1115-20. (Pubitemid 35177364)
46. Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001;163:469-73. (Pubitemid 32158530)
47. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83. (Pubitemid 46718402)
48. Bauer AK, Malkinson AM, Kleeberger SR. Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice:genetic similarities. Am J Physiol Lung Cell Mol Physiol 2004;287:L685-703. (Pubitemid 39249381)
49. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator. DJ-1 Am JRespir Crit Care Med 2008;178:592-604.
50. Lawless MW, O'Byrne KJ, Gray SG. Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med 2009;13:2800-21.
51. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3:235-43.
52. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25:4358-64. (Pubitemid 350013840)
53. Garg K, Keith RL, Byers T, et al. Randomized controlled trial with low-dose spiral CT for lung cancer screening:feasibility study and preliminary results. Radiology 2002;225:506-10. (Pubitemid 35239255)
54. Schwartz AG, Ruckdeschel JC. Familial lung cancer:genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:16-22. (Pubitemid 43069784)
55. Qu P, Roberts J, Li Y, et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009;63:341-7.
56. Young RP, Hopkins RJ, Hay BA, et al. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J 2009;85:515-24.
57. Palcic B, Garner DM, Beveridge J, et al. Increase of sensitivity of sputum cytology using high-resolution image cytometry:field study results. Cytometry 2002;50(3):168-76. (Pubitemid 37517316)
58. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010;67(2):170-6.
59. Phillips M, Cataneo RN, Cummin AR, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003;123:2115-23. (Pubitemid 36706741)
60. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17.
61. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:712-9. (Pubitemid 46536487)
62. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
63. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer:analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
64. Lee JM, Yanagawa J, Peebles KA, et al. Inflammation in lung carcinogenesis:new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008;66:208-17.
65. Kim ES, Hong WK, Lee JJ, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 2010;3:148-59.
66. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
67. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98: 1817-24. (Pubitemid 350002184)
68. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008;134:1278-86.
69. van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality:the influence of statins. Thorax 2009;64:963-7.
70. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008;68:29-36.
71. Myzak MC, Karplus PA, Chung FL, et al. A novel mechanism of chemoprotection by sulforaphane:inhibition of histone deacetylase. Cancer Res 2004;64:5767-74. (Pubitemid 39095576)
72. Lawless MW, Norris S, O'Byrne KJ, et al. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. Endocr Metab Immune Disord Drug Targets 2009;9:84-107.
73. Cheung KL, Khor TO, Kong AN. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res 2009;26:224-31.
74. Sriram N, Kalayarasan S, Sudhandiran G. Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol Pharm Bull 2008;31:1306-11. (Pubitemid 351930637)
75. Shirai T, Reshad K, Yoshitomi A, et al. Green tea-induced asthma:relationship between immunological reactivity, specific and non-specific bronchial responsiveness. Clin Exp Allergy 2003;33:1252-5. (Pubitemid 37108530)
76. Whyte L, Huang YY, Torres K, et al. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res 2007;67:12007-17.
77. Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease:needs and opportunities for integrated research. J Natl Cancer Inst 2009;101: 554-9.